Current Edition

announces

Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson’s Disease Published in JAMA Neurology

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that results …

Continue Reading →